BiotechTube

High intensity lipid lowering

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

May 15, 2020 → Apr 17, 2024

NCT ID
NCT05368545

About High intensity lipid lowering

High intensity lipid lowering is a pre-clinical stage product being developed by HeartFlow for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05368545. Target conditions include Coronary Artery Disease.

Hype Score Breakdown

Clinical
5
Activity
2
Company
5
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05368545Pre-clinicalCompleted

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
ExenatideEli LillyPhase 3
77
Clopidogrel treatment groupYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
85
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
77
statins, ezetimibe + Combination therapyYuhanApproved
85
YH14659 + clopidogrel & aspirinYuhanPhase 1
33
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
85
clopidogrel + prasugrelDaiichi SankyoPhase 1
33
PrasugrelDaiichi SankyoApproved
85
ADP receptor inhibitorsDaiichi SankyoPre-clinical
23
Pactimibe, CS-505Daiichi SankyoPhase 2
52
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
52
prasugrel + clopidogrelDaiichi SankyoPhase 1
33
Prasugrel + ClopidogrelDaiichi SankyoApproved
85
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
77
Placebo + PrasugrelDaiichi SankyoPhase 3
77
30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
85

Other Products from HeartFlow

EvolocumabApproved
80
Rosuvastatin 40mg + PlaceboPre-clinical
18